Human VEGFR2/KDR Quantikine ELISA Kit | R&D Systems DVR200 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

ELISA/assay

product name :

Human VEGFR2/KDR Quantikine ELISA Kit

catalog :

DVR200

quantity :

1 Kit (also 1 Pack (50 Plates), 1 Pack (6 Plates))

price :

655 USD

citations: 37

Reference
Zarychta E, Bielawski K, Wrzeszcz K, Rhone P, Ruszkowska Ciastek B. Unraveling the Angiogenic Puzzle: Pre-Treatment sVEGFR1 and sVEGFR2 Levels as Promising Prognostic Indicators in Early-Stage Breast Cancer Patients. Int J Mol Sci. 2023;24: pubmed publisher
Rosiek V, Janas K, Kos Kud x142 a B. Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues. Biomedicines. 2023;11: pubmed publisher
Fornaro L, Musettini G, Orlandi P, Pecora I, Vivaldi C, Banchi M, et al. Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer. Am J Cancer Res. 2022;12:3347-3356 pubmed
Jiguet Jiglaire C, Boissonneau S, Denicolaï E, Hein V, Lasseur R, Garcia J, et al. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathol Commun. 2022;10:1 pubmed publisher
Zilberman L, Zalik A, Fugenfirov I, Shimoni S, George J, Goland S. Residual alterations of cardiac and endothelial function in patients who recovered from Takotsubo cardiomyopathy. Clin Cardiol. 2021;44:797-804 pubmed publisher
Waszczykowska A, Podgórski M, Waszczykowski M, Gerlicz Kowalczuk Z, Jurowski P. Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report. Int J Mol Sci. 2020;21: pubmed publisher
Dong D, Fu Y, Chen F, Zhang J, Jia H, Li J, et al. Hyperoxia sensitizes hypoxic HeLa cells to ionizing radiation by downregulating HIF‑1α and VEGF expression. Mol Med Rep. 2021;23: pubmed publisher
Barbara R, Piotr R, Kornel B, El x17c bieta Z, Danuta R, Eduardo N. Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes. J Clin Med. 2020;9: pubmed publisher
Fountzilas C, Gupta M, Lee S, Krishnamurthi S, Estfan B, Wang K, et al. A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. Br J Cancer. 2020;122:963-970 pubmed publisher
Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, et al. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol. 2019;19:167 pubmed publisher
Zarychta E, Rhone P, Bielawski K, Michalska M, Rosc D, Ruszkowska Ciastek B. Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants. Adv Med Sci. 2019;64:216-223 pubmed publisher
Sánchez Ramírez J, Morera Díaz Y, Bequet Romero M, Hernandez Bernal F, Selman Housein Bernal K, de la Torre Santos A, et al. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants. BMC Immunol. 2017;18:39 pubmed publisher
Kalender G, Kornberger A, Lisy M, Beiras Fernandez A, Stock U. Kinetics of circulating endothelial progenitor cells in patients undergoing carotid artery surgery. Ther Clin Risk Manag. 2016;12:1841-1847 pubmed publisher
Panta S, Yamakuchi M, Shimizu T, Takenouchi K, Oyama Y, Koriyama T, et al. Low grade inflammation inhibits VEGF induced HUVECs migration in p53 dependent manner. Biochem Biophys Res Commun. 2017;483:803-809 pubmed publisher
Salazar R, Capdevila J, Laquente B, Manzano J, Pericay C, Villacampa M, et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015;15:60 pubmed publisher
Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla Herttuala S, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer. 2014;14:696 pubmed publisher
Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, et al. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. Br J Cancer. 2014;110:26-33 pubmed publisher
Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer. 2013;13:263 pubmed publisher
Abu El Asrar A, Nawaz M, Kangave D, Mairaj Siddiquei M, Geboes K. Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res. 2013;2013:539658 pubmed publisher
Jurgensmeier J, Schmoll H, Robertson J, Brooks L, Taboada M, Morgan S, et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer. 2013;108:1316-23 pubmed publisher
Somlo G, Atzori F, Strauss L, Geese W, Specht J, Gradishar W, et al. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res. 2013;19:1884-93 pubmed publisher
Widemann B, Kim A, Fox E, Baruchel S, Adamson P, Ingle A, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012;18:6011-22 pubmed publisher
Sleijfer S, Gorlia T, Lamers C, Burger H, Blay J, Le Cesne A, et al. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br J Cancer. 2012;107:639-45 pubmed publisher
Harmon C, DePrimo S, Raymond E, Cheng A, Boucher E, Douillard J, et al. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med. 2011;9:120 pubmed publisher
Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F, et al. Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res. 2011;31:2589-95 pubmed
DuBois S, Shusterman S, Ingle A, Ahern C, Reid J, Wu B, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011;17:5113-22 pubmed publisher
de Groot J, Piao Y, Tran H, Gilbert M, Wu H, Liu J, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011;17:4872-81 pubmed publisher
Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer. 2011;104:1262-9 pubmed publisher
Farace F, Gross Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, et al. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer. 2011;104:1144-50 pubmed publisher
Konings I, de Jonge M, Burger H, van der Gaast A, van Beijsterveldt L, Winkler H, et al. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br J Cancer. 2010;103:987-92 pubmed publisher
Zhu A, Sahani D, Duda D, di Tomaso E, Ancukiewicz M, Catalano O, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027-35 pubmed publisher
Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. Fertil Steril. 2010;94:52-7 pubmed publisher
Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, et al. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther. 2009;17:278-84 pubmed publisher
Burstein H, Elias A, Rugo H, Cobleigh M, Wolff A, Eisenberg P, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810-6 pubmed publisher
Saltz L, Rosen L, Marshall J, Belt R, Hurwitz H, Eckhardt S, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25:4793-9 pubmed
Norden Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 2007;13:2643-50 pubmed
Wallner W, Sengenberger R, Strick R, Strissel P, Meurer B, Beckmann M, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond). 2007;112:51-7 pubmed

product information

master code :

DVR200

SKU :

DVR200

product name :

Human VEGFR2/KDR Quantikine ELISA Kit

unit size :

1 Kit (also 1 Pack (50 Plates), 1 Pack (6 Plates))

description :

The Human VEGFR2/KDR Quantikine ELISA Kit from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human VEGFR2/KDR/Flk-1 in cell culture supernates (100 ul), cell lysates (100 ul), serum (20 ul), edta plasma (20 ul), heparin plasma (20 ul).

target :

VEGFR2/KDR/Flk-1

category :

ELISAs

species :

Human

specificity :

Natural and recombinant human VEGF R2

gene symbol :

KDR

kit type :

Solid Phase Sandwich ELISA

assay length :

4.5 hours

elisaSampleTypes :

Cell Culture Supernates (100 uL), Cell Lysates (100 uL), Serum (20 uL), EDTA Plasma (20 uL), Heparin Plasma (20 uL)

elisaSensitivity :

11.4 pg/mL

elisaRange :

78.10 - 5000 pg/mL

top caption :

Human VEGF R2/KDR/Flk-1 ELISA Standard Curve

applications :

ELISA

USD :

655 USD

product details :

The Quantikine Human VEGF R2 Immunoassay is a 4.5 hour solid-phase Immunoassay designed to measure human soluble VEGF R2 in cell culture supernates, cell lysates, serum, and plasma. It contains NS0-expressed recombinant human VEGF R2/Fc Chimera and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human VEGF R2 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human soluble VEGF R2.

alt names :

CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), KRD1, Ly73, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2

storage :

Store the unopened product at 2 - 8 ░C. Do not use past expiration date.